Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Common Equity (2016 - 2026)

Organogenesis Holdings has reported Common Equity over the past 11 years, most recently at $300.1 million for Q4 2025.

  • For Q4 2025, Common Equity rose 14.16% year-over-year to $300.1 million; the TTM value through Dec 2025 reached $300.1 million, up 14.16%, while the annual FY2025 figure was $300.1 million, 14.16% up from the prior year.
  • Common Equity for Q4 2025 was $300.1 million at Organogenesis Holdings, up from $255.1 million in the prior quarter.
  • Over five years, Common Equity peaked at $300.1 million in Q4 2025 and troughed at $153.0 million in Q1 2021.
  • A 5-year average of $249.0 million and a median of $259.6 million in 2022 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: soared 448.65% in 2021 and later decreased 12.63% in 2025.
  • Year by year, Common Equity stood at $241.3 million in 2021, then increased by 10.08% to $265.7 million in 2022, then grew by 4.89% to $278.7 million in 2023, then fell by 5.66% to $262.9 million in 2024, then increased by 14.16% to $300.1 million in 2025.
  • Business Quant data shows Common Equity for ORGO at $300.1 million in Q4 2025, $255.1 million in Q3 2025, and $233.2 million in Q2 2025.